Draft NICE guidance does not recommend Aimovig in migraine.- Novartis.
In draft guidelines, the National Institute for Health and Care Excellence (NICE) has announced that it has decided that Aimovig (erenumab), from Novartis, cannot be funded by the NHS as preventative treatment for migraine. Aimovig was approved for use in Europe last year as the first treatment specifically designed to prevent migraine.
The EU approval is based on the phase IIIb LIBERTY trial, which assessed Aimovig in episodic migraine patients who had previously tried two to four therapies without success, showing that patients taking the drug had almost three-fold higher odds of having migraine days cut by half or more versus placebo. More than twice as many patients taking Aimovig achieved this reduction.
However, NICE argued that the evidence from the LIBERTY trial doesn�t fully reflect patients seen in clinical practice in the NHS and nor does it include all the relevant comparators and outcomes. The result of this is that cost-effectiveness estimates for the drug are higher than those normally considered acceptable.
Related news and insights
Fabhalta is a Factor B inhibitor that acts proximally in the alternative complement pathway of the immune system, providing comprehensive control of red blood cell (RBC) destruction within and outside the blood vessels (intra- and extravascular hemolysis [IVH and EVH])
Merck KGaA, a leading science and technology company, announced that its two Phase III EVOLUTION clinical trials (evolution RMS 1 and evolution RMS 2) investigating the efficacy and safety of evobrutinib did not meet their primary endpoints of reducing annualized relapse rates (ARR) in people with relapsing multiple sclerosis (RMS) compared to oral teriflunomide (Aubagio) (0.11 vs. 0.11 in evolution RMS 1 and 0.15 for evobrutinib vs. 0.14 for teriflunomide in evolution RMS 2, p=NS in both trials)